Assessment Status | Awaiting full HTA submission from Applicant |
HTA ID | 23048 |
Drug | Fenfluramine (Fintepla®) |
Brand | Fintepla® |
Indication | Fenfluramine (Fintepla®) is indicated for seizures associated with Dravet Syndrome (as an add-on therapy for patients two years of age and older). |
Assessment Process | |
Rapid review commissioned | 31/07/2023 |
Rapid review completed | 07/09/2023 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fenfluramine compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 29/09/2023 |
Pre-submission consultation with Applicant | 07/11/2023 |